Detalles de la búsqueda
1.
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.
BMC Health Serv Res
; 22(1): 1066, 2022 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35987627
2.
Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Int J Technol Assess Health Care
; 37: e31, 2021 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33509311
3.
Using IMPrESS to guide policy change in multiple sclerosis.
Mult Scler
; 24(9): 1251-1255, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29064774
4.
DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS.
Int J Technol Assess Health Care
; 34(5): 498-506, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30251618
5.
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries.
Eur J Health Econ
; 24(7): 1023-1031, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36219363
6.
Does external reference pricing deliver what it promises? Evidence on its impact at national level.
Eur J Health Econ
; 21(1): 129-151, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31583483
7.
Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients.
Health Policy
; 123(2): 159-165, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30598239
Resultados
1 -
7
de 7
1
Próxima >
>>